ADC Therapeutics

ADC Therapeutics
Partner Level

Company Overview

ADC Therapeutics. Confronting cancer with the full potential of our science.

ADC Therapeutics is a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody drug conjugates (ADCs. ADC Therapeutics is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.


For general inquiries, please contact:

For Medical Information inquiries, please contact:

For more information about ADC Therapeutics, including latest news

ADC Therapeutics Latest News


Report Adverse Reactions or Product Complaints

To report suspected adverse events or product complaints, please call us at 1-855-690-0340 and select prompt 1.

You may also call the FDA at 1-800-FDA-1088 or report suspected adverse events at

Patient Support

Personalized assistance and support

Our dedicated case managers can serve as a single point of contact and are there every step of the way—to help patients get started and stay on ZYNLONTA.

Contact one of our case managers at 1-855-690-0340 Monday-Friday (8 AM—8 PM ET). Enroll your patients at

For commercially insured patients, 18 years of age and older with coverage for ZYNLONTA. Patients are not eligible if they participate in any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medicare Part D or Medicare Advantage plan, VA, DOD, or TRICARE. Excludes patients who are uninsured or full cash-paying. Maximum benefit per patient, per calendar year (1/1—12/31) is $25,000. Additional eligibility requirements and other restrictions apply.


Advancing Patient Support Website

Our Product

ZYNLONTA HCP Website  |   Twitter  |   YouTube

To request a Sales Representative

Request a Representative


© 2021 FLASCO | Premium Website Design by The HDG